4-(羧甲基)苯硼酸 | 90111-58-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(羧甲基)苯硼酸
• 中文别名: 4-羧甲基苯硼酸
• 英文名称: 2-(4-boronophenyl)acetic acid
• 英文别名: 4-(carboxymethyl)phenylboronic acid
• CAS: 90111-58-3
• 化学式: C₈H₉BO₄
• mdl: MFCD03425919
• 分子量: 179.968
• InChiKey: NFGJQVPDPIGBJE-UHFFFAOYSA-N

物化性质

• 熔点：
  158-160°C
• 沸点：
  416.1±47.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2931900090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温下保存，避免光照，并保持干燥和密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Carboxymethylphenylboronic acid
Synonyms: 2-(4-Boronophenyl)acetic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Carboxymethylphenylboronic acid
CAS number: 90111-58-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9BO4
Molecular weight: 180.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(羧甲基)苯硼酸 在 N-甲基吗啉 、 四丁基溴化铵 、 palladium diacetate 、 sodium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 27.0h， 生成 N-[[4-(aminomethyl)phenyl]methyl]-2-[4-(2,3,4,5,6-pentafluorophenyl)phenyl]acetamide
  参考文献：
  名称：

  使用基于新结构的分子设计发现联苯乙酰胺衍生的BACE1抑制剂

  摘要：

  β-分泌酶（BACE1）是淀粉样蛋白-β肽生产中第一步和限速步骤的酶，是治疗阿尔茨海默氏病的诱人靶标。在这项研究中，我们报告了基于从头片段的分子设计程序SPROUT在基于联苯乙酰胺支架的一系列非肽BACE1抑制剂的发现中的应用。从最初的BACE1 IC 50开始，基于这种设计的分子支架的分子的结合亲和力增加了在合成了优化配体库之后，使用最新开发的SPROUT-HitOpt软件对323μM至27μM的分子进行了精制。尽管发现许多抑制剂表现出细胞毒性，但是发现该系列中的一种化合物在细胞测定中具有有用的BACE1抑制活性，并且细胞毒性最小。这项工作证明了基于计算机模拟片段的分子设计方法在发现新型BACE1抑制剂中的强大功能。

  DOI：

  10.1021/jm301127x
• 作为产物：
  描述：

  4-(溴甲基)苯硼酸 在 sodium hydroxide 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 4-(羧甲基)苯硼酸
  参考文献：
  名称：

  芳基硼化合物-VIII：羟基和羧苯基硼酸的一些反应

  摘要：

  羧基和羟基苯基硼酸（I-VI）的一些新的衍生物已被制备并直接卤化邻位和对位羟基和甲氧基苯基酸进行了研究。

  DOI：

  10.1016/s0040-4020(01)99333-0

文献信息

• [EN] SUBSTITUTED 1,6-NAPHTHYRIDINES<br/>[FR] 1,6-NAPHTYRIDINES SUBSTITUÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014079787A1

  公开（公告）日：2014-05-30

  The present invention relates to the use of compounds of general formula (I) wherein R' is hydrogen or lower alkyl; R1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)-NH-lower alkyl, CH2-C(O)-NH-lower alkyl, CH2-NH-C(O)-lower alkyl, CH2NH2, S(O)2CH3, S(O)2N(CH3)2, or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH3)2; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, NH-S(O)2-CH3, -(CH2)m-O-lower alkyl or -(CH2)n-S(O)2-CH3; or is -(CR2)n-phenyl, optionally substituted by -S(O)2CH3 or lower alkoxy; or is -(CH2)n-heterocycloalkyl, optionally substituted by lower alkyl and =O; or is -(CH2)n-heteroaryl, optionally substituted by one or two lower alkyl groups; or is -(CH2)n-cycloalkyl, optionally substituted by cyano; or R2 and R3 form together with the N atom to which they are attached a heterocyclic ring, selected from morpholine, piperidine, 1, 1-dioxo-thiomorpholine or piperazine which may be substituted by lower alkyl or C(O)O-lower alkyl, or may form a pyrrolidine ring, optionally substituted by hydroxy; R is independently from n hydrogen or lower alkyl; n is 0, 1, 2, 3; m is 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction ("chemobrain"), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及使用一般式（I）的化合物，其中R'是氢或较低的烷基；R1是卤素、较低的烷基、环烷基或氰基；或者是苯基，可选择地被一个到三个取代基取代，所述取代基选自较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、卤素、氰基、羟基、C(O)-NH-较低烷基、CH2-C(O)-NH-较低烷基、CH2-NH-C(O)-较低烷基、CH2NH2、S(O)2CH3、S(O)2N(CH3)2，或者是由杂环烷基组成的基团；或者是吡唑-1、4或5-基，可选择地被较低烷基取代；或者是噻唑-5-基，可选择地被一个或两个较低烷基基团取代；或者是吡啶-2、3或4-基，可选择地被较低烷基、较低烷氧基、卤素或N(CH3)2取代；或者是3,6-二氢-2H-吡喃；或者是苯并[d][1,3]二噁嗪-5-基；或者是2,3-二氢苯并[b][1,4]二噁烷-6-基；R2是氢、较低烷基或被烷氧基取代的较低烷基；R3是氢、较低烷基、被卤素取代的较低烷基、被羟基取代的较低烷基、NH-S(O)2-CH3、-(CH2)m-O-较低烷基或-(CH2)n-S(O)2-CH3；或者是-(CR2)n-苯基，可选择地被-S(O)2CH3或较低烷氧基取代；或者是-(CH2)n-杂环烷基，可选择地被较低烷基和=O取代；或者是-(CH2)n-杂芳基，可选择地被一个或两个较低烷基基团取代；或者是-(CH2)n-环烷基，可选择地被氰基取代；或者R2和R3与它们连接的N原子一起形成一个杂环环，所述杂环环选自吗啉、哌啶、1,1-二氧代-硫代吗啉或哌嗪，可被较低烷基或C(O)O-较低烷基取代，或者可形成一个吡咯烷环，可选择地被羟基取代；R独立于n是氢或较低烷基；n为0、1、2、3；m为2；或者是药学上可接受的酸盐，或者是外消旋混合物，或者是其对应的对映体和/或光学异构体，用于治疗精神分裂症、强迫性人格障碍、抑郁症、躁郁症、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍（“化疗脑”）、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化症、亨廷顿病、中风，以及由放射治疗、慢性应激、视神经病变或黄斑变性引起的干扰，或者由酒精、阿片类药物、甲基苯丙胺、芬太尼或可卡因等神经活性药物的滥用引起的干扰。
• [EN] CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CYSTEINE PROTEASE
  申请人：MEDIVIR AB

  公开号：WO2005066180A1

  公开（公告）日：2005-07-21

  A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  一个公式为(II)的化合物，其中R1和R2中的一个是卤素，另一个是H或卤素；R3是C1-C4直链或支链，可选择氟代的烷基；R4是H；或者R3与R4和相邻的骨架碳一起定义：一个螺环C5-C7环烷基，可选地用1至3个卤素、羟基、C1-C4烷基或C1-C4卤代烷基中的取代基取代；或者可选地用亚甲基桥接；或者是一个具有O、NRa、S、S(=O)2等异原子的C4-C6饱和杂环；其中Ra是H、C1-C4烷基或CH3C(=O)；R5独立地选择自H或甲基；E是-C(=O)-、-S(=O)m-、-NR5S(=O)m-、-NR5C(=O)-、-OC(=O)-；R6是稳定的、可选择取代的、单环或双环的、碳环或杂环；m独立地为0、1或2；是猫hepsin K的抑制剂，并且在骨质疏松症的治疗或预防中有用。
• [EN] 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS DE 3-ARYLISOQUINOL-1-ONE 5-SUBSTITUÉE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：CANCER RES INST ROYAL

  公开号：WO2015036759A1

  公开（公告）日：2015-03-19

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. Formula (I)

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些3-芳基-5-取代-2/-/-异喹啉-1-酮化合物，该化合物在抑制PARP（例如PARP1、TNKS1、TNKS2等）和/或Wnt信号传导方面具有作用。本发明还涉及包含此类化合物的药物组合物，以及使用这些化合物和组合物在体外和体内抑制PARP（例如PARP1、TNKS1、TNKS2等）；抑制Wnt信号传导；治疗通过抑制PARP（例如PARP1、TNKS1、TNKS2等）改善的疾病；治疗通过抑制Wnt信号传导改善的疾病；治疗增生性疾病如癌症等。公式（I）
• Discovery of Potent and Selective PI3Kγ Inhibitors
  作者：Samuel L. Drew、Rhiannon Thomas-Tran、Joel W. Beatty、Jeremy Fournier、Kenneth V. Lawson、Dillon H. Miles、Guillaume Mata、Ehesan U. Sharif、Xuelei Yan、Artur K. Mailyan、Elaine Ginn、Jie Chen、Kent Wong、Divyank Soni、Puja Dhanota、Pei-Yu Chen、Stefan G. Shaqfeh、Cesar Meleza、Amber T. Pham、Ada Chen、Xiaoning Zhao、Jesus Banuelos、Lixia Jin、Ulrike Schindler、Matthew J. Walters、Stephen W. Young、Nigel P. Walker、Manmohan Reddy Leleti、Jay P. Powers、Jenna L. Jeffrey

  DOI：10.1021/acs.jmedchem.0c01203

  日期：2020.10.8

  The selective inhibition of the lipid signaling enzyme PI3Kγ constitutes an opportunity to mediate immunosuppression and inflammation within the tumor microenvironment but is difficult to achieve due to the high sequence homology across the class I PI3K isoforms. Here, we describe the design of a novel series of potent PI3Kγ inhibitors that attain high isoform selectivity through the divergent projection

  脂质信号传导酶PI3Kγ的选择性抑制构成了在肿瘤微环境中介导免疫抑制和炎症的机会，但由于I类PI3K同工型之间的高度序列同源性而难以实现。在这里，我们描述了一系列新型的有效PI3Kγ抑制剂的设计，这些抑制剂通过取代基发散地投射到PI3Kγ的三磷酸腺苷（ATP）结合位点的“选择性”和“烷基诱导”口袋中而获得了高同工型选择性。这些努力最终导致发现了5- [2-氨基-3-（1-甲基-1 H-吡唑-4-基）吡唑并[1,5 - a ]嘧啶-5-基] -2-[（ 1 S）-1-环丙基乙基] -7-（三氟甲基）-2,3-二氢-1 H-异吲哚-1-酮（如图4所示，IC 50＝0.064μM，THP-1细胞），其对PI3Kγ的选择性比其他I类同工型显示出> 600倍的选择性，并且是朝着临床候选者的鉴定迈出的有希望的一步。在整个运动过程中发现的结构-活性关系表明，抑制剂可以占据“烷基诱导的”口袋，并具有能够与
• Importance of Binding Site Hydration and Flexibility Revealed When Optimizing a Macrocyclic Inhibitor of the Keap1–Nrf2 Protein–Protein Interaction
  作者：Fabio Begnini、Stefan Geschwindner、Patrik Johansson、Lisa Wissler、Richard J. Lewis、Emma Danelius、Andreas Luttens、Pierre Matricon、Jens Carlsson、Stijn Lenders、Beate König、Anna Friedel、Peter Sjö、Stefan Schiesser、Jan Kihlberg

  DOI：10.1021/acs.jmedchem.1c01975

  日期：2022.2.24

  Upregulation of the transcription factor Nrf2 by inhibition of the interaction with its negative regulator Keap1 constitutes an opportunity for the treatment of disease caused by oxidative stress. We report a structurally unique series of nanomolar Keap1 inhibitors obtained from a natural product-derived macrocyclic lead. Initial exploration of the structure-activity relationship of the lead, followed

  通过抑制与其负调节因子 Keap1 的相互作用来上调转录因子 Nrf2 构成了治疗由氧化应激引起的疾病的机会。我们报告了从天然产物衍生的大环铅中获得的一系列结构独特的纳摩尔级 Keap1 抑制剂。对先导化合物的构效关系进行初步探索，然后进行结构导向优化，使抑制效力提高了 100 倍。纳摩尔抑制剂的大环核心定位三个药效团单元，用于与 Keap1 的关键残基（包括 R415、R483 和 Y572）进行有效相互作用。配体优化导致配位水分子从 Keap1 结合位点移位，并显着改变热力学曲线。此外，R415 和 R483 的微小重组伴随着配体之间亲和力的重大差异。因此，本研究表明在设计高亲和力配体时考虑 Keap1 结合位点的水合作用和灵活性的重要性。